November 2, 2009
CESAR Prize for Translational Anticancer Research awarded to Matthias Tacke

The CESAR Prize 2009 for Translational Anticancer Research was awarded to Dr Matthias Tacke during the CESAR Autumn Symposium, which was held from October 29-31, 2009 in Heidelberg at the German Cancer Research Centre (DKFZ) in order to celebrate 10 years of CESAR's (Central European Society for Anticancer Drug Research) activities.

Dr Matthias Tacke (PhD 1990 in Münster, Habilitation 1997 in Karlsruhe) is a Senior Lecturer at UCD's School of Chemistry and Chemical Biology and a Conway Fellow working in the Centre for Synthesis and Chemical Biology. Since 2002 Dr. Tacke's research group has synthesised titanium and vanadium-based metallocene anticancer drug candidates, which are tested in cooperation with CESAR in preclinical in vitro and in vivo cancer models. In the meantime the compounds show nanomolar cytotoxic and anti-angiogenic activity and will be ready to enter clinical trials in the nearby future.

Photo: Prof. Dr Max Scheulen, Dr M Tacke, Prof Dr U Jaehde

L-R - Prof. Dr Max E. Scheulen, President of Award
and Fellowship Selection Committee (AFSC), Dr Matthias Tacke,
Prof. Dr Ulrich Jaehde, new President of CESAR

The president of CESAR Prof. Dr. Ulrich Jaehde congratulated both winners of the CESAR Prize 2009 and looks forward to enhanced cooperation within the CESAR network.

The CESAR Prize is given for contributions towards translational research leading to the development of anticancer drugs in a preclinical or clinical setting. The prize, which is given biannually, is meant to stimulate innovation in the field of translational anticancer research. The CESAR Prize can be shared and is worth €6,000.


More News